Dai Ichi Life Insurance Company Ltd lessened its stake in shares of TESARO, Inc. (NASDAQ:TSRO) by 70.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,643 shares of the biopharmaceutical company’s stock after selling 20,858 shares during the quarter. Dai Ichi Life Insurance Company Ltd’s holdings in TESARO were worth $1,209,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its position in TESARO by 2.1% in the 1st quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 60 shares during the last quarter. Profund Advisors LLC raised its position in TESARO by 3.8% in the 1st quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $394,000 after purchasing an additional 93 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in TESARO by 0.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock valued at $2,576,000 after purchasing an additional 150 shares during the last quarter. Aperio Group LLC raised its position in TESARO by 4.5% in the 2nd quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 156 shares during the last quarter. Finally, Stephens Inc. AR raised its position in TESARO by 11.0% in the 1st quarter. Stephens Inc. AR now owns 1,759 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 175 shares during the last quarter.

In other news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the sale, the vice president now owns 6,258 shares of the company’s stock, valued at $844,329.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,100 shares of company stock valued at $3,387,465. 40.50% of the stock is currently owned by company insiders.

TESARO, Inc. (NASDAQ:TSRO) opened at 117.16 on Friday. The firm has a 50-day moving average price of $121.74 and a 200-day moving average price of $140.42. TESARO, Inc. has a 1-year low of $96.52 and a 1-year high of $192.94. The firm’s market capitalization is $6.35 billion.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the previous year, the business posted ($1.28) earnings per share. The business’s revenue was down 17.6% on a year-over-year basis. Equities analysts expect that TESARO, Inc. will post ($8.67) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Dai Ichi Life Insurance Company Ltd Has $1.21 Million Position in TESARO, Inc. (TSRO)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/16/dai-ichi-life-insurance-company-ltd-has-1-21-million-position-in-tesaro-inc-tsro.html.

Several equities analysts have issued reports on the company. Oppenheimer Holdings, Inc. assumed coverage on TESARO in a research report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective for the company. Cann reissued an “outperform” rating on shares of TESARO in a research note on Wednesday, May 24th. Credit Suisse Group set a $198.00 target price on TESARO and gave the company a “buy” rating in a research note on Monday, June 5th. FBR & Co lowered their target price on TESARO from $200.00 to $195.00 and set a “mkt perform” rating for the company in a research note on Monday, June 5th. Finally, Wedbush raised TESARO to an “outperform” rating and set a $168.00 target price for the company in a research note on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $171.42.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.